MedPath
HSA Product

MENQUADFI SOLUTION FOR INJECTION

Product approved by Health Sciences Authority (SG)

Basic Information

MENQUADFI SOLUTION FOR INJECTION

INJECTION, SOLUTION

Regulatory Information

SIN16454P

March 29, 2022

Prescription Only

Therapeutic

INTRAMUSCULAR

August 10, 2023

May 30, 2025

XJ07AH08

Company Information

SANOFI-AVENTIS SINGAPORE PTE. LTD.

SANOFI-AVENTIS SINGAPORE PTE. LTD.

Active Ingredients

Detailed Information

Contraindications

**Contraindications** Hypersensitivity to the active substances or to any of the excipients listed in section List of excipients or after previous administration of the vaccine or a vaccine containing the same components – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.

Indication Information

**Therapeutic indications** MenQuadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by _Neisseria meningitidis_ serogroups A, C, W, and Y. The use of this vaccine should be in accordance with available official recommendations.

© Copyright 2025. All Rights Reserved by MedPath